AIM IMMUNOTECH INC(AIMID.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
AIM IMMUNOTECH INC
AIMID.US
1.921 T
AIMID.USMarket value -Rank by Market Cap -/-

Financial Score

06/02/2026 Update
E
BiotechnologyIndustry
Industry Ranking393/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-10862.86%E
    • Profit Margin-10416.44%E
    • Gross Margin37.50%B
  • Growth ScoreD
    • Revenue YoY-24.35%E
    • Net Profit YoY51.13%B
    • Total Assets YoY-61.41%E
    • Net Assets YoY-179.92%E
  • Cash ScoreD
    • Cash Flow Margin-0.96%D
    • OCF YoY-24.35%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreE
    • Gearing Ratio161.73%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Aimed Bio Q4 Operating Profit 25.3 Billion Won, Up 200% From Year Earlier

    Aimed Bio Inc :AIMED BIO: Q4 OPERATING PROFIT 25.3 BILLION WON, UP 200% FROM YEAR EARLIER

    Reuters·
    US
    AIM
    -7.89%
    US
    AIMID
    0.00%
    Reuters·
    US
    AIM
    -7.89%
    US
    AIMID
    0.00%

    3 Global Growth Companies With High Insider Ownership Expecting Up To 116% Earnings Growth

    In a volatile week for global markets, U.S. stock indexes declined amid trade concerns, but an upward revision of U.S. GDP growth presents opportunities for investors. Companies with high insider ownership, such as Aimed Bio, Oscotec, and BHI, show promising earnings growth forecasts of up to 116%. Aimed Bio focuses on brain disease therapeutics, Oscotec on drug development, and BHI on power plant equipment, all indicating strong fundamentals despite market fluctuations. Insider ownership suggests confidence in their strategic visions, making them appealing investment options.

    Simplywall·
    US
    AIMID
    0.00%
    Simplywall·
    US
    AIMID
    0.00%

    AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

    AIM Vaccine updates on 20-valent pneumococcal polysaccharide conjugate vaccine

    marketscreener·
    US
    AIMID
    0.00%
    marketscreener·
    US
    AIMID
    0.00%

    AIM ImmunoTech Inc. is giving a stock dividend of one share for every 1,000 shares to be distributed on January 13, 2026.

    AIM ImmunoTech Inc. announced a stock dividend plan on December 30, 2025, where one share will be distributed for every 1,000 shares of outstanding common stock. This applies to eligible options or warrants termed as "Alternate Securities." The dividend will be allocated to stockholders and Alternate Securities holders recorded as of January 9, 2026, with distribution occurring on January 13, 2026.

    Unusual Whales·
    US
    AIMID
    0.00%
    Unusual Whales·
    US
    AIMID
    0.00%

    Trump Secures Deals With Nine Pharma Firms To Lower US Drug Prices, Avert Tariffs

    US President Trump announced deals with nine pharmaceutical firms to lower drug prices in exchange for three-year tariff exemptions. The agreements cover price reductions for various treatments and commit firms to "Most Favored Nation" pricing for Medicaid. The TrumpRx platform will offer direct-to-consumer sales at discounted rates. The deals aim to provide savings for uninsured patients, while critics question the transparency and impact on drug development.

    Talkmarkets·
    US
    AIMID
    0.00%
    Talkmarkets·
    US
    AIMID
    0.00%
    Posts
    View More
    © 2026 Longbridge｜Disclaimer